Recombinant virus expressing interleukin-12
US-2026071233-A1 · Mar 12, 2026 · US
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C12N2710/24032 |
| Official title | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| Display label | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| Total patents | 31 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is stable.
| Year | Patents |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 2 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Oncolytic virus platform to treat hematological cancer
US-12569526-B2 · Mar 10, 2026 · US
Enhancing oncolytic virotherapy with a combination of nuclear export inhibitor and myxoma virus activating cell death pathways
US-2025387443-A1 · Dec 25, 2025 · US
Oncolytic virus expressing a car t cell target and uses thereof
US-2025381237-A1 · Dec 18, 2025 · US
Cancer therapies comprising a nuclear export inhibitor and an oncolytic virus
US-2025249056-A1 · Aug 7, 2025 · US
Oncolytic virus expressing a car T cell target and uses thereof
US-12364724-B2 · Jul 22, 2025 · US
Oncolytic virus platform to treat cancers with myxoma virus
US-12331079-B2 · Jun 17, 2025 · US
Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US-2025177518-A1 · Jun 5, 2025 · US
Oncolytic virotherapy compositions and methods
US-2025121017-A1 · Apr 17, 2025 · US
Composition and methods including recombinant viruses modulating arginine biosynthesis
US-2024316130-A1 · Sep 26, 2024 · US
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US-12036279-B2 · Jul 16, 2024 · US
Oncolytic viruses that express multi-specific immune cell engagers
US-2024093158-A1 · Mar 21, 2024 · US
Oncolytic virus comprising immunomodulatory transgenes and uses thereof
US-2024091284-A1 · Mar 21, 2024 · US
Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC
US-11591616-B1 · Feb 28, 2023 · US
Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US-2023057304-A1 · Feb 23, 2023 · US
Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
US-2022296660-A1 · Sep 22, 2022 · US
Genetically engineered oncolytic vaccinia viruses and methods of uses thereof
US-2022290179-A1 · Sep 15, 2022 · US
Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US-11285209-B2 · Mar 29, 2022 · US
A new oncolytic virus platform to treat cancers with myxoma virus
US-2021324014-A1 · Oct 21, 2021 · US
Oncolytic virus platform to treat cancers with myxoma virus
US-11117934-B2 · Sep 14, 2021 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C12N2710/24032?
- CPC C12N2710/24032 is the Cooperative Patent Classification code for “Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent.”
- How many patents are filed under CPC C12N2710/24032 (Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent)?
- Our database includes 31 publications tagged with this CPC code.
- Is patent activity under CPC C12N2710/24032 growing?
- Publication counts under this code: 4 in 2024 vs 7 in 2025 (latest complete years).